Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

Nicole DeFeudis

Editor

Roche’s tiragolumab flop earlier this quarter set the program back at least a year, Severin Schwan revealed on the company’s Q2 call — but the outgoing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron forges ahead in factor XI despite field’s mixed results

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug

In blow to compounders, FDA reaffirms tirzepatide shortage is over

Roche plots new course for tiragolum­ab as ex­ecs nav­i­gate biosim­i­lar chal­lenges and de­clin­ing Covid-19 sales

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

Roche plots new course for tiragolumab as execs navigate biosimilar challenges and declining Covid-19 sales

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron forges ahead in factor XI despite field’s mixed results

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

FDA rejects Zealand Pharma's short bowel syndrome drug

In blow to compounders, FDA reaffirms tirzepatide shortage is over